Related Experiment Videos

CD30L up-regulates CD30 and IL-4 expression by T cells

F M Rossi1, M Degan, L Mazzocut-Zecchin

  • 1Clinical and Experimental Hematology Research Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Via Pedemontana Occ.le 12, 33081 (PN), Aviano, Italy.

FEBS Letters
|December 1, 2001
PubMed

Insights

Acute myeloid leukemia (AML) cells expressing CD30L promote a non-protective T-helper 2 (Th2) immune response. This involves increased interleukin-4 (IL-4) production, suggesting CD30L as a therapeutic target in AML.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • CD30L is frequently expressed on acute myeloid leukemia (AML) blasts.
  • CD30L expression correlates with interleukin-4 (IL-4) receptor co-expression and T-helper 2 (Th2) cell expansion.

Purpose of the Study:

  • To investigate the role of CD30L expressed by AML blasts in modulating the immune response.
  • To determine the direct impact of CD30L on T cell polarization and cytokine production.

Main Methods:

  • Co-culture of T cells with recombinant CD30L-bearing cells and with AML blasts.
  • Analysis of surface CD30 expression, IL-4 production, and soluble CD30 (sCD30) release.
  • Use of blocking anti-CD30 antibodies to assess CD30L function.

Main Results:

  • Recombinant CD30L induced CD30 expression and increased IL-4 and sCD30 production in T cells.
  • AML blasts expressing CD30L similarly enhanced IL-4 production and sCD30 release in co-cultured T cells.
  • Anti-CD30 antibodies blocked sCD30 release and reduced IL-4 production, confirming CD30L's role.

Conclusions:

  • CD30L on AML blasts directly drives a Th2-polarized immune response.
  • This Th2 polarization is associated with a non-protective immune state in AML.
  • Targeting CD30L may represent a novel therapeutic strategy for AML.

Related Concept Videos